HeartSciences (HSCSW) Equity Average (2021 - 2026)

HeartSciences has reported Equity Average for 6 years, with the latest figure at $3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 17.77% year-over-year to $3.4 million; the trailing twelve-month figure through Jan 2026 stood at $3.4 million (up 17.77% YoY), and the FY2025 full-year result was $3.8 million, changed 0.34% from the prior year.
• Equity Average for Q1 2026 stood at $3.4 million, down from $3.7 million in the prior quarter.
• The five-year high for Equity Average was $8.0 million in Q2 2024, with the low at -$5.1 million in Q2 2022.
• Historically, Equity Average has averaged $1.6 million across 5 years, with a median of $1.7 million in 2025.
• Annual changes were most pronounced in 2023 — Equity Average sank 154.65% — and 2024, when it soared 58411.6%.
• HeartSciences' Equity Average stood at $2.0 million in 2022, then plunged by 154.65% to -$1.1 million in 2023, then surged by 558.69% to $5.0 million in 2024, then retreated by 26.4% to $3.7 million in 2025, then decreased by 6.68% to $3.4 million in 2026.
• The last three Equity Average figures came in at $3.4 million (Q1 2026), $3.7 million (Q4 2025), and $1.7 million (Q3 2025), per Business Quant data.